The Cardinal Health (CAH) has shown significant stock market performance recently, capturing the attention of value investors. Despite missing on Q1 revenue estimates, it exceeded profit expectations, amounting to a $109M settlement to investors. The stock witnessed an all-time high of $155 and $140.69. These trends occurred alongside the reporting of third quarter fiscal year 2025 results and an uplifting of the 2025 outlook, which was favorably reviewed by Jim Cramer and other market analysts.
Dividends have increased to $0.5107 per quarter, with expected growth despite tariff headwinds. The company has made strategic acquisitions in the cell and gene therapy industry and has expanded its gastroenterology and diabetes businesses with deals worth $3.9 billion. In the face of looming tariff costs, Cardinal Health has downsized its workforce. However, the company remains on track on meeting its growth expectations in fiscal year 2025.
The company has been associated with Morgan Stanley and Telix for launching Gozellix Imaging Agent. However, analysts hold mixed opinions on whether the stock will continue to rise.
Cardinal Health CAH News Analytics from Wed, 14 Aug 2024 07:00:00 GMT to Fri, 23 May 2025 18:08:55 GMT - Rating 4 - Innovation -2 - Information 8 - Rumor -5
